A Phase 1b/2 Study Evaluating Efficacy and Safety of MP0250, a Designed Ankyrin Repeat Protein (darpin) Simultaneously Targeting Vascular Endothelial Growth Factor (VEGF) and Hepatocyte Growth Factor (HGF), in Combination with Bortezomib and Dexamethasone, in Patients with Relapsed or Refractory Multiple Myeloma
EJHAEM（2024）
Key words
anti-HGF,anti-VEGF,DARPin,MP0250,refractory/relapsed multiple myeloma
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined